Physician profile
German Ramirez
NPI 1669583555
$4,996.10
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $721 · 2021: $992 · 2022: $1,016 · 2023: $1,562 · 2024: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,697 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,696.90 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $875.17 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $685.01 | 2019-2023 | Farxiga, Lokelma, Evusheld |
| Bayer Healthcare Pharmaceuticals INC. | $644.82 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $507.91 | 2019-2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $502.82 | 2020-2024 | Terlivaz, Acthar |
| Amgen INC. | $483.24 | 2019-2024 | Repatha, Krystexxa, Otezla |
| Mallinckrodt Enterprises LLC | $207.74 | 2019 | |
| Glaxosmithkline, LLC. | $165.99 | 2021-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $144.29 | 2019-2024 | |
| Travere Therapeutics, INC. | $133.90 | 2019-2023 | |
| Lilly USA, LLC | $101.44 | 2019-2023 | Mounjaro |
| Calliditas Therapeutics US INC. | $90.66 | 2023 | Tarpeyo |
| Akebia Therapeutics INC | $75.66 | 2019-2023 | Auryxia |
| Opko Pharmaceuticals, LLC | $62.24 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $57.50 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.52 | 2023 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $45.70 | 2023 | Inpefa |
| Ani Pharmaceuticals, INC. | $43.67 | 2022 | |
| Vifor Pharma, INC. | $43.18 | 2021 | |
| Esperion Therapeutics, INC. | $15.47 | 2021 | |
| Ardelyx, INC. | $15.34 | 2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $14.65 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.33 | 2019 | |
| Novo Nordisk INC | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw German Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.